Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer

The rate of esophagogastric cancer is rising among individuals under 50 years of age. It remains unknown whether early-onset esophagogastric cancer represents a unique entity. This study investigated the clinical and molecular characteristics of early-onset and average-onset esophagogastric cancer ....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JNCI : Journal of the National Cancer Institute Jg. 116; H. 2; S. 299
Hauptverfasser: Lumish, Melissa A, Walch, Henry, Maron, Steven B, Chatila, Walid, Kemel, Yelena, Maio, Anna, Ku, Geoffrey Y, Ilson, David H, Won, Elizabeth, Li, Jia, Joshi, Smita S, Gu, Ping, Schattner, Mark A, Laszkowska, Monika, Gerdes, Hans, Jones, David R, Sihag, Smita, Coit, Daniel G, Tang, Laura H, Strong, Vivian E, Molena, Daniela, Stadler, Zsofia K, Schultz, Nikolaus, Janjigian, Yelena Y, Cercek, Andrea
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 08.02.2024
Schlagworte:
ISSN:1460-2105, 1460-2105
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract The rate of esophagogastric cancer is rising among individuals under 50 years of age. It remains unknown whether early-onset esophagogastric cancer represents a unique entity. This study investigated the clinical and molecular characteristics of early-onset and average-onset esophagogastric cancer . We reviewed the Memorial Sloan Kettering Cancer Center gastric, esophageal, and gastroesophageal junction cancer database. Associations between baseline characteristics and tumor and germline molecular alterations were compared between those with early-onset and average-onset esophagogastric cancer using Fisher exact tests and the Benjamini-Hochberg method for multiple-hypothesis correction. We included 1123 patients with early-onset esophagogastric cancer (n = 219; median age = 43 years [range = 18-49 years]) and average-onset esophagogastric cancer (n = 904; median age = 67 years [range = 50-94 years]) treated between 2005 and 2018. The early-onset group had more women (39% vs 28%, P = .002). Patients with early-onset esophagogastric cancer were more likely to have a gastric primary site (64% vs 44%, P < .0001). The signet ring cell and/or diffuse type was 3 times more common in the early-onset esophagogastric cancer group (31% vs 9%, P < .0001). Early-onsite tumors were more frequently genomically stable (31% vs 18%, P = .0002) and unlikely to be microsatellite instability high (2% vs 7%, P = .003). After restricting to adenocarcinoma and signet ring cell and/or diffuse type carcinomas, we observed no difference in stage (P = .40) or overall survival from stage IV diagnosis (median = 22.7 vs 22.1 months, P = .78). Our study supported a preponderance of gastric primary disease sites, signet ring histology, and genomically stable molecular subtypes in early-onset esophagogastric cancer. Our findings highlight the need for further research to define the underlying pathogenesis and strategies for early detection and prevention.
AbstractList The rate of esophagogastric cancer is rising among individuals under 50 years of age. It remains unknown whether early-onset esophagogastric cancer represents a unique entity. This study investigated the clinical and molecular characteristics of early-onset and average-onset esophagogastric cancer . We reviewed the Memorial Sloan Kettering Cancer Center gastric, esophageal, and gastroesophageal junction cancer database. Associations between baseline characteristics and tumor and germline molecular alterations were compared between those with early-onset and average-onset esophagogastric cancer using Fisher exact tests and the Benjamini-Hochberg method for multiple-hypothesis correction. We included 1123 patients with early-onset esophagogastric cancer (n = 219; median age = 43 years [range = 18-49 years]) and average-onset esophagogastric cancer (n = 904; median age = 67 years [range = 50-94 years]) treated between 2005 and 2018. The early-onset group had more women (39% vs 28%, P = .002). Patients with early-onset esophagogastric cancer were more likely to have a gastric primary site (64% vs 44%, P < .0001). The signet ring cell and/or diffuse type was 3 times more common in the early-onset esophagogastric cancer group (31% vs 9%, P < .0001). Early-onsite tumors were more frequently genomically stable (31% vs 18%, P = .0002) and unlikely to be microsatellite instability high (2% vs 7%, P = .003). After restricting to adenocarcinoma and signet ring cell and/or diffuse type carcinomas, we observed no difference in stage (P = .40) or overall survival from stage IV diagnosis (median = 22.7 vs 22.1 months, P = .78). Our study supported a preponderance of gastric primary disease sites, signet ring histology, and genomically stable molecular subtypes in early-onset esophagogastric cancer. Our findings highlight the need for further research to define the underlying pathogenesis and strategies for early detection and prevention.
The rate of esophagogastric cancer is rising among individuals under 50 years of age. It remains unknown whether early-onset esophagogastric cancer represents a unique entity. This study investigated the clinical and molecular characteristics of early-onset and average-onset esophagogastric cancer .BACKGROUNDThe rate of esophagogastric cancer is rising among individuals under 50 years of age. It remains unknown whether early-onset esophagogastric cancer represents a unique entity. This study investigated the clinical and molecular characteristics of early-onset and average-onset esophagogastric cancer .We reviewed the Memorial Sloan Kettering Cancer Center gastric, esophageal, and gastroesophageal junction cancer database. Associations between baseline characteristics and tumor and germline molecular alterations were compared between those with early-onset and average-onset esophagogastric cancer using Fisher exact tests and the Benjamini-Hochberg method for multiple-hypothesis correction.METHODSWe reviewed the Memorial Sloan Kettering Cancer Center gastric, esophageal, and gastroesophageal junction cancer database. Associations between baseline characteristics and tumor and germline molecular alterations were compared between those with early-onset and average-onset esophagogastric cancer using Fisher exact tests and the Benjamini-Hochberg method for multiple-hypothesis correction.We included 1123 patients with early-onset esophagogastric cancer (n = 219; median age = 43 years [range = 18-49 years]) and average-onset esophagogastric cancer (n = 904; median age = 67 years [range = 50-94 years]) treated between 2005 and 2018. The early-onset group had more women (39% vs 28%, P = .002). Patients with early-onset esophagogastric cancer were more likely to have a gastric primary site (64% vs 44%, P < .0001). The signet ring cell and/or diffuse type was 3 times more common in the early-onset esophagogastric cancer group (31% vs 9%, P < .0001). Early-onsite tumors were more frequently genomically stable (31% vs 18%, P = .0002) and unlikely to be microsatellite instability high (2% vs 7%, P = .003). After restricting to adenocarcinoma and signet ring cell and/or diffuse type carcinomas, we observed no difference in stage (P = .40) or overall survival from stage IV diagnosis (median = 22.7 vs 22.1 months, P = .78).RESULTSWe included 1123 patients with early-onset esophagogastric cancer (n = 219; median age = 43 years [range = 18-49 years]) and average-onset esophagogastric cancer (n = 904; median age = 67 years [range = 50-94 years]) treated between 2005 and 2018. The early-onset group had more women (39% vs 28%, P = .002). Patients with early-onset esophagogastric cancer were more likely to have a gastric primary site (64% vs 44%, P < .0001). The signet ring cell and/or diffuse type was 3 times more common in the early-onset esophagogastric cancer group (31% vs 9%, P < .0001). Early-onsite tumors were more frequently genomically stable (31% vs 18%, P = .0002) and unlikely to be microsatellite instability high (2% vs 7%, P = .003). After restricting to adenocarcinoma and signet ring cell and/or diffuse type carcinomas, we observed no difference in stage (P = .40) or overall survival from stage IV diagnosis (median = 22.7 vs 22.1 months, P = .78).Our study supported a preponderance of gastric primary disease sites, signet ring histology, and genomically stable molecular subtypes in early-onset esophagogastric cancer. Our findings highlight the need for further research to define the underlying pathogenesis and strategies for early detection and prevention.CONCLUSIONSOur study supported a preponderance of gastric primary disease sites, signet ring histology, and genomically stable molecular subtypes in early-onset esophagogastric cancer. Our findings highlight the need for further research to define the underlying pathogenesis and strategies for early detection and prevention.
Author Schultz, Nikolaus
Joshi, Smita S
Cercek, Andrea
Tang, Laura H
Molena, Daniela
Janjigian, Yelena Y
Jones, David R
Gerdes, Hans
Won, Elizabeth
Maio, Anna
Sihag, Smita
Kemel, Yelena
Ilson, David H
Coit, Daniel G
Chatila, Walid
Li, Jia
Strong, Vivian E
Ku, Geoffrey Y
Maron, Steven B
Walch, Henry
Lumish, Melissa A
Gu, Ping
Schattner, Mark A
Laszkowska, Monika
Stadler, Zsofia K
Author_xml – sequence: 1
  givenname: Melissa A
  orcidid: 0000-0003-4173-5567
  surname: Lumish
  fullname: Lumish, Melissa A
  organization: Department of Medicine, Weill Cornell Medical College, New York, NY, USA
– sequence: 2
  givenname: Henry
  orcidid: 0000-0003-1188-350X
  surname: Walch
  fullname: Walch, Henry
  organization: Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
– sequence: 3
  givenname: Steven B
  surname: Maron
  fullname: Maron, Steven B
  organization: Department of Medicine, Weill Cornell Medical College, New York, NY, USA
– sequence: 4
  givenname: Walid
  orcidid: 0000-0001-5474-218X
  surname: Chatila
  fullname: Chatila, Walid
  organization: Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
– sequence: 5
  givenname: Yelena
  orcidid: 0000-0002-5042-5651
  surname: Kemel
  fullname: Kemel, Yelena
  organization: Robert and Kate Niehaus Center for Inherited Cancer Genomics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
– sequence: 6
  givenname: Anna
  surname: Maio
  fullname: Maio, Anna
  organization: Robert and Kate Niehaus Center for Inherited Cancer Genomics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
– sequence: 7
  givenname: Geoffrey Y
  orcidid: 0000-0002-0448-1038
  surname: Ku
  fullname: Ku, Geoffrey Y
  organization: Department of Medicine, Weill Cornell Medical College, New York, NY, USA
– sequence: 8
  givenname: David H
  orcidid: 0000-0003-0831-2247
  surname: Ilson
  fullname: Ilson, David H
  organization: Department of Medicine, Weill Cornell Medical College, New York, NY, USA
– sequence: 9
  givenname: Elizabeth
  orcidid: 0000-0001-5901-750X
  surname: Won
  fullname: Won, Elizabeth
  organization: Department of Medicine, Weill Cornell Medical College, New York, NY, USA
– sequence: 10
  givenname: Jia
  surname: Li
  fullname: Li, Jia
  organization: Department of Medicine, Weill Cornell Medical College, New York, NY, USA
– sequence: 11
  givenname: Smita S
  surname: Joshi
  fullname: Joshi, Smita S
  organization: Department of Medicine, Weill Cornell Medical College, New York, NY, USA
– sequence: 12
  givenname: Ping
  surname: Gu
  fullname: Gu, Ping
  organization: Department of Medicine, Weill Cornell Medical College, New York, NY, USA
– sequence: 13
  givenname: Mark A
  surname: Schattner
  fullname: Schattner, Mark A
  organization: Gastroenterology, Hepatology and Nutrition Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
– sequence: 14
  givenname: Monika
  orcidid: 0000-0001-6816-3293
  surname: Laszkowska
  fullname: Laszkowska, Monika
  organization: Gastroenterology, Hepatology and Nutrition Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
– sequence: 15
  givenname: Hans
  surname: Gerdes
  fullname: Gerdes, Hans
  organization: Gastroenterology, Hepatology and Nutrition Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
– sequence: 16
  givenname: David R
  surname: Jones
  fullname: Jones, David R
  organization: Department of Surgery Memorial, Sloan Kettering Cancer Center, New York, NY, USA
– sequence: 17
  givenname: Smita
  surname: Sihag
  fullname: Sihag, Smita
  organization: Department of Surgery Memorial, Sloan Kettering Cancer Center, New York, NY, USA
– sequence: 18
  givenname: Daniel G
  orcidid: 0000-0001-8901-1555
  surname: Coit
  fullname: Coit, Daniel G
  organization: Department of Surgery Memorial, Sloan Kettering Cancer Center, New York, NY, USA
– sequence: 19
  givenname: Laura H
  surname: Tang
  fullname: Tang, Laura H
  organization: Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
– sequence: 20
  givenname: Vivian E
  surname: Strong
  fullname: Strong, Vivian E
  organization: Department of Surgery Memorial, Sloan Kettering Cancer Center, New York, NY, USA
– sequence: 21
  givenname: Daniela
  surname: Molena
  fullname: Molena, Daniela
  organization: Department of Surgery Memorial, Sloan Kettering Cancer Center, New York, NY, USA
– sequence: 22
  givenname: Zsofia K
  surname: Stadler
  fullname: Stadler, Zsofia K
  organization: Robert and Kate Niehaus Center for Inherited Cancer Genomics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
– sequence: 23
  givenname: Nikolaus
  surname: Schultz
  fullname: Schultz, Nikolaus
  organization: Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
– sequence: 24
  givenname: Yelena Y
  surname: Janjigian
  fullname: Janjigian, Yelena Y
  organization: Department of Medicine, Weill Cornell Medical College, New York, NY, USA
– sequence: 25
  givenname: Andrea
  orcidid: 0000-0002-5054-8192
  surname: Cercek
  fullname: Cercek, Andrea
  organization: Department of Medicine, Weill Cornell Medical College, New York, NY, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37699004$$D View this record in MEDLINE/PubMed
BookMark eNpNkD1rwzAYhEVJaT7arXPR2MWNJMuSPZbQLwh0acdiXsuvEwVZSiU7kH_fQFPoLXccDzfcnEx88EjILWcPnFX5cueNXbY7aHmpLsiMS8UywVkx-ZenZJ7Sjp1UCXlFprlWVcWYnJGvlbPeGnAUfEv74NCMDiI1W4hgBow2DdYkGjqKEN0xCz7hQA-JwgEjbPBcYAr7LWzCBtIQraEGvMF4TS47cAlvzr4gn89PH6vXbP3-8rZ6XGdGymLIoCkYyLLLu6ZqlNSNFtxIbYxWuTDYcCUw71psBeoux6IwbaWY0E2nFZSiEgty_7u7j-F7xDTUvU0GnQOPYUy1KJVUvCyr8oTendGx6bGt99H2EI_13yXiB7X6Z0k
CitedBy_id crossref_primary_10_1111_jgh_17012
crossref_primary_10_1016_j_intimp_2024_113436
crossref_primary_10_1371_journal_pone_0315391
crossref_primary_10_3390_curroncol32090480
crossref_primary_10_3748_wjg_v30_i38_4221
crossref_primary_10_4251_wjgo_v16_i3_583
crossref_primary_10_1016_S0140_6736_25_00052_2
crossref_primary_10_1186_s12885_025_13767_z
crossref_primary_10_1007_s10120_023_01443_9
crossref_primary_10_1038_s41698_025_01030_4
crossref_primary_10_1080_08998280_2025_2488592
crossref_primary_10_1002_cam4_70451
crossref_primary_10_1007_s10120_025_01584_z
crossref_primary_10_1177_26345161251354937
crossref_primary_10_1186_s12957_025_03867_2
crossref_primary_10_1038_s41598_025_08618_7
crossref_primary_10_1097_MD_0000000000038098
ContentType Journal Article
Copyright The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Copyright_xml – notice: The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1093/jnci/djad186
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1460-2105
ExternalDocumentID 37699004
Genre Research Support, U.S. Gov't, Non-P.H.S
Review
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: P30 CA008748
– fundername: NIH HHS
GroupedDBID ---
-E4
-~X
.2P
.I3
.XZ
.ZR
08P
0R~
1TH
29L
2WC
354
4.4
482
48X
5GY
5RE
5VS
5WD
70D
96U
AABZA
AACZT
AAHTB
AAJKP
AAMVS
AAOGV
AAPNW
AAPQZ
AAPXW
AARHZ
AAUAY
AAVAP
AAWTL
ABCQX
ABDFA
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABNHQ
ABNKS
ABOCM
ABPEJ
ABPPZ
ABPTD
ABQLI
ABQNK
ABVGC
ABXVV
ABZBJ
ACBMB
ACGFO
ACGFS
ACGOD
ACKOT
ACNCT
ACPRK
ACUFI
ACUTO
ACYHN
ADBBV
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADNBA
ADOCK
ADQBN
ADRTK
ADVEK
ADYVW
AEGPL
AEJOX
AEKSI
AEMDU
AEMQT
AENZO
AEPUE
AETBJ
AEWNT
AFAZI
AFFNX
AFFZL
AFIYH
AFOFC
AFRAH
AFXAL
AFYAG
AGINJ
AGKEF
AGORE
AGSYK
AGUTN
AHGBF
AHMBA
AHMMS
AHXPO
AIAGR
AIJHB
AJBYB
AJEEA
AJNCP
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APWMN
ATGXG
BAWUL
BAYMD
BCRHZ
BEYMZ
BTRTY
BVRKM
C45
CDBKE
CGR
CS3
CUY
CVF
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBS
ECM
EE~
EIF
EMOBN
ENERS
F5P
F8P
F9B
FECEO
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HW0
HZ~
IH2
IOX
J21
JXSIZ
KAQDR
KOP
KQ8
KSI
KSN
L7B
M-Z
MHKGH
ML0
N9A
NGC
NOMLY
NOYVH
NPM
NU-
OAUYM
OAWHX
OBH
OCB
OCZFY
ODMLO
ODZKP
OGEVE
OHH
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
PAFKI
PEELM
PQQKQ
Q.-
Q1.
Q5Y
R44
RD5
RNS
ROL
ROX
ROZ
RUSNO
RW1
RXO
TCURE
TEORI
TJX
TMA
TR2
TWZ
UDS
UPT
VVN
W8F
WH7
WOQ
X7H
YAYTL
YKOAZ
YQT
YXANX
ZKX
ZRR
ZY1
~91
~H1
7X8
ID FETCH-LOGICAL-c445t-ab50a48f3fb9b647b721c47cc7632ceb162e3fded2e7f3e55cd96027bf76a8292
IEDL.DBID 7X8
ISICitedReferencesCount 23
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001103540500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1460-2105
IngestDate Thu Oct 02 12:04:21 EDT 2025
Tue Jun 17 01:30:27 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c445t-ab50a48f3fb9b647b721c47cc7632ceb162e3fded2e7f3e55cd96027bf76a8292
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ORCID 0000-0002-5042-5651
0000-0003-4173-5567
0000-0002-0448-1038
0000-0002-5054-8192
0000-0003-1188-350X
0000-0001-6816-3293
0000-0003-0831-2247
0000-0001-8901-1555
0000-0001-5901-750X
0000-0001-5474-218X
OpenAccessLink https://pmc.ncbi.nlm.nih.gov/articles/PMC10852615/pdf/djad186.pdf
PMID 37699004
PQID 2864618898
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2864618898
pubmed_primary_37699004
PublicationCentury 2000
PublicationDate 2024-02-08
PublicationDateYYYYMMDD 2024-02-08
PublicationDate_xml – month: 02
  year: 2024
  text: 2024-02-08
  day: 08
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle JNCI : Journal of the National Cancer Institute
PublicationTitleAlternate J Natl Cancer Inst
PublicationYear 2024
SSID ssj0000924
Score 2.556843
SecondaryResourceType review_article
Snippet The rate of esophagogastric cancer is rising among individuals under 50 years of age. It remains unknown whether early-onset esophagogastric cancer represents...
The rate of esophagogastric cancer is rising among individuals under 50 years of age. It remains unknown whether early-onset esophagogastric cancer represents...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 299
SubjectTerms Adenocarcinoma - epidemiology
Adenocarcinoma - genetics
Adolescent
Adult
Aged
Aged, 80 and over
Carcinoma, Signet Ring Cell - metabolism
Carcinoma, Signet Ring Cell - pathology
Cardia - metabolism
Esophageal Neoplasms - epidemiology
Esophageal Neoplasms - genetics
Esophagogastric Junction - metabolism
Esophagogastric Junction - pathology
Female
Humans
Middle Aged
Retrospective Studies
Stomach Neoplasms - diagnosis
Stomach Neoplasms - epidemiology
Stomach Neoplasms - genetics
Young Adult
Title Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/37699004
https://www.proquest.com/docview/2864618898
Volume 116
WOSCitedRecordID wos001103540500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvVvC6NNlsNpuTiFg82NKDQi9S9lkqmtSm9vc7m2wpHgTByx4CCWGY_XZm5-P7ELqJs9hJRQ2JrI0IU04QKVQEizO-bZapqtX1n7J-XwyH-SBcuFWBVrnExBqoTan9HXmHCs54LEQubqefxLtG-elqsNBYR60EShlP6cqGK7XwKG9MbRmPCLQ2aSC-QxPfeSv0pGPepIkF_724rA-Z7u5_f28P7YTyEt81-bCP1mxxgLZ6YYB-iF6DDug7loXBH0tvXKx_6jbj0mHrpY-JJ1vP8aLCEnIesCc8sN79QI7LsfS-HxprnzyzI_TSfXi-fyTBYYFoxtI5kSqNJBMucSpXnGUK-kHNMq0BdagGGOfUJs5YQ23mEpum2kDHQzPlMi4Fzekx2ijKwp4izHRCI2UTrmQOJRhV8FlHXa4tN7EztI2ul4EbQQb7sYQsbPlVjVaha6OTJvqjaSO1MQL4g-MyYmd_ePscbVOoOGpKtbhALQf7116iTb2YT6rZVZ0asPYHvW8-3ceF
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+and+molecular+characteristics+of+early-onset+vs+average-onset+esophagogastric+cancer&rft.jtitle=JNCI+%3A+Journal+of+the+National+Cancer+Institute&rft.au=Lumish%2C+Melissa+A&rft.au=Walch%2C+Henry&rft.au=Maron%2C+Steven+B&rft.au=Chatila%2C+Walid&rft.date=2024-02-08&rft.issn=1460-2105&rft.eissn=1460-2105&rft.volume=116&rft.issue=2&rft.spage=299&rft_id=info:doi/10.1093%2Fjnci%2Fdjad186&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1460-2105&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1460-2105&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1460-2105&client=summon